Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome

Objective: to evaluate the efficacy of melatonin and clonazepam versus placebo in patients with burning mouth syndrome (BMS). Methods: a prospective double-blind study was carried out in patients with BMS and randomized to three groups: melatonin (1 mg once a day), clonazepam (0.5 mg/twice a day), o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Candela Castillo-Felipe, Asta Tvarijonaviciute, Marina López-Arjona, Luis Pardo-Marin, Eduardo Pons-Fuster, Pia López-Jornet
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Assuntos:
burning mouth syndrome
pain
xerostomia
sleep
melatonin
clonazepam
Acceso en liña:https://www.mdpi.com/2077-0383/11/9/2516
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares